Skip to main content
SpringerLink
Log in

Health-related quality of life in cardiac patients with dyslipidemia and hypertension

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Background: Hypertension is associated with lower health-related quality of life (HRQOL). Similar association may be found for dyslipidemia. However, controversies exist regarding the HRQOL with dyslipidemia. We evaluated the HRQOL of cardiac patients with and without dyslipidemia and hypertension. Methods: In a cross-sectional study, 284 cardiac patients rated their HRQOL using SF-36 Health Survey (SF-36), and three preference-based measures (Rating Scale, Time Trade-off and Standard Gamble). Results: Compared to those without dyslipidemia, those with dyslipidemia reported better HRQOL on all preference-based measures and most SF-36 scales particularly on the physical health scales. Adjusted mean differences and 95% confidence interval (95% CI) were equal to 4.5 (0.5, 8.5), 10.8 (2.8, 18.8), and 2.2 (0.2, 4.2) on the Physical Functioning, the Role-Physical and the Physical Component Summary scales, respectively. Exactly the opposite trends were observed among patients with hypertension. The adjusted mean differences (95% CI) were equal to −2.7 (−6.7, 1.4), −10.9 (−19.1, −2.8), and −2.9 (−4.9, −0.9) on the Physical Functioning, the Role-Physical and the Physical Component Summary scales, respectively. Conclusion: Cardiac patients with hypertension reported lower physical health than those without hypertension while cardiac patients with dyslipidemia reported better physical health than those without dyslipidemia. The reason for these different trends is not known. Possible explanations are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Monk M. Blood pressure awareness and psychological well-being in the health and nutrition examination survey. Clin Invest Med 1981; 4(3/4): 183-189.

    Google Scholar 

  2. Bloom JR, Monterossa S. Hypertension labeling and sense of well-being. Am J Public Health 1981; 71: 1228-1232.

    Google Scholar 

  3. Soghikian K, Fallick-Hunkeler EM, Ury HK, Fisher AA. The effect of high blood pressure awareness and treatment on emotional well-being. Clin Invest Med 1981; 4(3/4): 191-196.

    Google Scholar 

  4. Milne BJ, Logan AG, Flanagan P. Alterations in health perception and life-style in treated hypertensives. J Chron Dis 1985; 38(1): 37-45.

    Google Scholar 

  5. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study. JAMA 1989; 262: 907-913.

    Google Scholar 

  6. Bardage C, Isacson D. Hypertension and health-related quality of life: An epidemiological study in Sweden. J Clin Epidemiol 2001; 54: 172-181.

    Google Scholar 

  7. Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BEK. Health status and hypertension: A population-based study. J Clin Epidemiol 1996; 49(11): 1239-1245.

    Google Scholar 

  8. Polk BF, Harlan LC, Cooper SP, et al. Disability days associated with detection and treatment in a hypertension control program. Am J Epidemiol 1984; 119(1): 44-53.

    Google Scholar 

  9. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978; 299: 741-744.

    Google Scholar 

  10. Charlson ME, Alderman M, Melcher L. Absenteeism and labelling in hypertensive subjects. Prevention of an adverse impact in those at high risk. Am J Med 1982; 73: 165-170.

    Google Scholar 

  11. Alderman MH, Charlson ME, Melcher LA. Labelling and absenteeism: The Massachusetts mutual experience. Clin Invest Med 1981; 4(3/4): 165-171.

    Google Scholar 

  12. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: The TAIM Study. Ann Int Med 1991; 114(8): 613-620.

    Google Scholar 

  13. The Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Int Med 1991; 151(7): 1413-1423.

    Google Scholar 

  14. Jachuck SJ, Brierley H, Jachuck S, Willcox PM. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982; 32: 103-105.

    Google Scholar 

  15. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664.

    Google Scholar 

  16. Havas S, Reisman J, Hsu L, Koumjian L. Does cholesterol screening result in negative labeling effects? Results of the Massachusetts Model Systems for Blood Cholesterol Screening Project. Arch Intern Med 1991; 151: 113-119.

    Google Scholar 

  17. Forrow L, Galkins D, Allshouse K, Delbanco T. Effects of cholesterol screening on health perceptions. Clin Res 1989; 37: 818A.

    Google Scholar 

  18. Irvine MJ, Logan AG. Is knowing your cholesterol number harmful? J Clin Epidemiol 1984; 47(2): 131-145.

    Google Scholar 

  19. Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA, The Canadian Collaborative Cardiac Assessment Group. Health-related quality of life in coronary heart disease prevention and treatment. J Clin Epidemiol 2001; 54: 1011-1018.

    Google Scholar 

  20. Lawrence WF, Fryback DG, Martin PA, et al. Cholesterol and health status in the Beaver Dam Health Outcomes Study (abstract). Med Decis Making 1994; 14: 436.

    Google Scholar 

  21. Lalonde L, Clarke AE, Joseph L, Grover SA, The Canadian Collaborative Cardiac Assessment Group. Conventional and chained standard gamble in the assessment of coronary heart disease prevention and treatment. Med Decis Making 1999; 19: 149-156.

    Google Scholar 

  22. Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA, The Canadian Collaborative Cardiac Assessment Group. Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Qual Life Res 1999; 8: 399-409.

    Google Scholar 

  23. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam health outcomes study: Initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102.

    Google Scholar 

  24. Goldman L, Cook EF, Mitchell N, Flatley M, Sherman H, Cohn PF. Pitfalls in the serial assessment of cardiac functional status. How a reduction in “ordinary” activity may reduce the apparent degree of cardiac compromise and give a misleading impression of improvement. J Chron Dis 1982; 35: 763-771.

    Google Scholar 

  25. Goldman L, Hashimoto B, Cook F, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. Circulation 1981; 64: 1227-1234.

    Google Scholar 

  26. Ware JE, Gandek B, for the IQOLA Project. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51(11): 903-912.

    Google Scholar 

  27. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institude, 1994.

    Google Scholar 

  28. Furlong W, Feeny D, Torrance G, Barr R, Horsman J. Guide to Design and Development of Health-State Utility Instrumentation. Hamilton, Canada: McMaster University University, 1990.

    Google Scholar 

  29. Morss SE, Lenert LA, Faustmann WO. The Side Effects of Anti-Psychotic Drugs and Patients' Quality of Life: Patient Education and Preference Assessment with Computers and Multimedia. Proceeding of the 17th annual Symposium on Computer Applications in Medical Care. New York: McGraw Hill, 1993: 17-22.

    Google Scholar 

  30. Fortin PR, Clarke AE, Joseph L, et al. Outcomes of total hip and knee replacement. Arthritis Rheum 1999; 42(8): 1722-1728.

    Google Scholar 

  31. Cleeman JI, Lenfant C. The National Cholesterol Education Program. Progress and prospects. JAMA 1998; 280(24): 2099-2104.

    Google Scholar 

  32. Frohlich J, Fodor G, McPherson R, Genest J, Langner N, for the Dyslipidemia Working Group of Health Canada. Rational for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim report. Can J Cardiol 1998; 14(Suppl A): 17A-21A.

    Google Scholar 

  33. Pearson TA, McBride PE, Miller NH, Smith SC. Task Force 8: Organization of preventive cardiology service. J Am Coll Cardiol 1996; 27: 1039-1047.

    Google Scholar 

  34. The EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-1582.

    Google Scholar 

  35. Keech A, on behalf of the Asian-Pacific CHD Risk Factor Collaborative Group. Risk factor management in CHD patients in Asia: Current status. Atherosclerosis 1998; 136(Suppl): S31.

    Google Scholar 

  36. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-342.

    Google Scholar 

  37. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.

    Google Scholar 

  38. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravasatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.

    Google Scholar 

  39. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349-1357.

    Google Scholar 

  40. Franklin BA, Kalm JK. Delayed progression or regression of coronary atherosclerosis with intensive risk factor modification. Effects of Diet, Drugs, and Exercise. Sports Med 1996; 22(5): 301-319.

    Google Scholar 

  41. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-1802.

    Google Scholar 

  42. Selwyn AP, Kinlay S, Libby P, Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation 1997; 95: 5-7.

    Google Scholar 

  43. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.

    Google Scholar 

  44. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-1500.

    Google Scholar 

  45. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Chair Aventis Pharma in ambulatory pharmaceutical care, University of Montreal, Canada

    Lyne Lalonde

  2. Reserch team in primary care, Cité de la Santé de Laval, Laval, Quebec, Canada

    Lyne Lalonde

  3. School of Nursing and Department of Epidemiology, University of Ottawa, Ontario, Canada

    Annette O'Connor

  4. Division of Clinical Epidemiology, Montreal General Hospital, Montreal, Quebec, Canada

    Lawrence Joseph

  5. Department of Mathematics and Statistics, Montreal, Quebec, Canada

    Lawrence Joseph

  6. Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada

    Lawrence Joseph & Steven A. Grover

  7. Centre for the Analysis of Cost-Effective Care, Division of Clinical Epidemiology, Montreal, Quebec, Canada

    Steven A. Grover

  8. Division of General Internal Medicine, Montreal General Hospital, Montreal, Quebec, Canada

    Steven A. Grover

  9. Department of Medicine, McGill University, Montreal, Quebec, Canada

    Steven A. Grover

Authors
  1. Lyne Lalonde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette O'Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Joseph
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven A. Grover
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lalonde, L., O'Connor, A., Joseph, L. et al. Health-related quality of life in cardiac patients with dyslipidemia and hypertension. Qual Life Res 13, 793–804 (2004). https://doi.org/10.1023/B:QURE.0000021695.26201.a0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:QURE.0000021695.26201.a0

Search

Navigation